AbbVie Inc (NYSE: ABBV) shares are advancing to their highest level since early July following a positive analyst action on the stock.
Citigroup analyst Andrew Baum upgraded shares of AbbVie from Neutral to Buy with a $90 price target, suggesting roughly 25% upside from current levels.
AbbVie will extract significant shareholder value from its proposed Allergan plc (NYSE: AGN) acquisition, given its "industry-leading commercial focus and patient/physician centricity," analyst Baum said.
Even within AbbVie's portfolio, the analyst said he thinks the market is underappreciating the commercial potential of both plaque psoriasis drug Skyrizi and rheumatoid arthritis drug Rinvoq.
The analyst said he expected optimal PBM access, given the sizeable Humira rebate and the company's managed market excellence.
Dispelling Citi's earlier fears over the anticipated impact of biosimilars, the Allergan transaction provides a reasonably secure earnings floor and dividend on which the multiple can expand, the firm said.
The valuation is likely to improve, as Phase 3 readouts and revenue from new drugs kick in, it added.
The Price Action
At last check, AbbVie shares were advancing 2.30% to $73.78.
The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J
Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company
Latest Ratings for ABBV
View More Analyst Ratings for ABBV
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J
- The Week Ahead In Biotech: Spotlight On ESMO Conference
- Teva Dips Into Medical Marijuana Market With Canndoc Distribution Deal
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.